Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

被引：12
|
作者：
Kuter, David J. [1 ]
Bussel, James B. [2 ,3 ]
Newland, Adrian [4 ]
Wasser, Jeffrey S. [5 ]
Lyons, Roger M. [6 ]
George, James N. [7 ]
Macik, Gail [8 ]
Nie, Kun [9 ]
Jun, Susie [9 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] New York Presbyterian Hosp, Dept Pediat, New York, NY USA
[3] New York Presbyterian Hosp, Dept Med, Div Hematol, New York, NY USA
[4] Royal London Hosp, Dept Hematol, London E1 1BB, England
[5] Manchester Mem Hosp, Manchester, CT USA
[6] Canc Care Ctr S Texas US Oncol, San Antonio, TX USA
[7] OUHSC, Hematol Oncol Sect, Oklahoma City, OK USA
[8] Univ Virginia, Charlottesville, VA USA
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.68.68
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：36 / 37
页数：2
相关论文
共 50 条
  • [21] Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
    Kuter, David J.
    Bussel, James B.
    Newland, Adrian
    Baker, Ross I.
    Lyons, Roger M.
    Wasser, Jeffrey
    Viallard, Jean-Francois
    Macik, Gail
    Rummel, Mathias
    Nie, Kun
    Jun, Susie
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (03) : 411 - 423
  • [22] Updated results from the single-arm, open-label, long-term efficacy and safety study of subcutaneous (SC) romiplostim in children with immune thrombocytopenia (ITP)
    Grainger, J.
    Bussel, J.
    Tarantino, M.
    Cooper, N.
    Beam, D.
    Despotovic, J.
    Maschan, A.
    Wang, K.
    Bowers, C.
    Eisen, M.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 41 - 41
  • [23] Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)
    Grainger, John
    Bussel, James B.
    Tarantino, Michael D.
    Cooper, Nichola
    Beam, Donald
    Despotovic, Jenny M.
    Maschan, Alexey A.
    Wang, Kejia
    Eisen, Melissa Jeanne
    Bowers, Charles
    [J]. BLOOD, 2019, 134
  • [24] SAFETY ANALYSIS OF LONG-TERM ROMIPLOSTIM USE IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)
    Rodeghiero, F.
    Provan, D.
    Cines, D.
    Stasi, R.
    Tarantino, M.
    Nie, K.
    Jun, S.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 73 - 74
  • [25] Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
    Saleh, Mansoor N.
    Bussel, James B.
    Cheng, Gregory
    Meyer, Oliver
    Bailey, Christine K.
    Arning, Michael
    Brainsky, Andres
    [J]. BLOOD, 2013, 121 (03) : 537 - 545
  • [26] A SINGLE-ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF SUBCUTANEOUS ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA
    Grainger, J.
    Bussel, J.
    Cooper, N.
    Tarantino, M.
    Blanchette, V.
    Despotovic, J.
    Maschan, A.
    Carpenter, N.
    Eisen, M.
    Mehta, B.
    [J]. HAEMATOLOGICA, 2017, 102 : 124 - 125
  • [27] Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label
    Kuter, Davrt J.
    Bussel, James B.
    Newland, Adrian
    de Wolf, Joost T. M.
    Guthrie, Troy
    Wasser, Jeffrey
    Gehl, Lara
    Nie, Kun
    Berger, Dietmar
    [J]. BLOOD, 2008, 112 (11) : 154 - 154
  • [28] Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
    Bussel, James B.
    Kuter, David J.
    Pullarkat, Vinod
    Lyons, Roger M.
    Guo, Matthew
    Nichol, Janet L.
    [J]. BLOOD, 2009, 113 (10) : 2161 - 2171
  • [29] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [30] Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study
    Mei, Heng
    Liu, Xiaofan
    Li, Yan
    Zhou, Hu
    Feng, Ying
    Gao, Guangxun
    Cheng, Peng
    Huang, Ruibin
    Yang, Linhua
    Hu, Jianda
    Hou, Ming
    Yao, Yazhou
    Liu, Li
    Wang, Yi
    Wu, Depei
    Zhang, Liansheng
    Zheng, Changcheng
    Shen, Xuliang
    Hu, Qi
    Liu, Jing
    Jin, Jie
    Luo, Jianmin
    Zeng, Yun
    Gao, Sujun
    Zhang, Xiaohui
    Zhou, Xin
    Shi, Qingzhi
    Xia, Ruixiang
    Xie, Xiaobao
    Jiang, Zhongxing
    Gao, Li
    Bai, Yuansong
    Xiong, Junye
    Li, Runzi
    Zou, Jianjun
    Niu, Ting
    Yang, Renchi
    Hu, Yu
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (03) : 716 - 728
12345